от ХХIV МЕЖДУНАРОДЕН КОНГРЕС ПО ЕХОКАРДИОГРАФИЯ

A_1. Percutaneous Treatment for Tricuspid Regurgitation

Steven Goldstein

Washington Hospital Center, Washington, DC, USA

Due to its common association with left-sided heart valve disease or cardiomyopathy, functional tricuspid regurgitation (TR) was merely considered as an innocent bystander and a reversible condition for a long time and management focused primarily on correction of the left-sided pathology. However, more recent data indicates that TR does NOT resolve after correction of left-sided heart disease. Moreover, even moderate TR (a common problem in clinical cardiology) represents a significant risk factor for progression to severe TR and is associated with significant morbidity and reduced long-term survival. Surgical approaches consist of Kay annuloplasty, DeVega annuloplasty, and annuloplasty ring. However, many patients have advanced co-morbidities making surgery high-risk and/or undesirable. A variety of emerging transcatheter techniques are an attractive alternative to surgery for these patients that are deemed to be high-risk surgical candidates. These can be categorized as: (1) annular modification (e.g., Tricinch; Trialign; Cardioband; Millipede; Triapta) (2) Spacers (Forma device) (3) leaflet apposition (MitraClip) and (4) caval valve implantation (TricValve; SAPIEN valve implanted in the svc and IVC). Some of these preclinical and early clinical novel transcatheter treatment options for patients with symptomatic functional TR and high surgical risk will be presented. 

For more abstracts see the attached file below.